| Title |
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
|
|---|---|
| Published in |
BMC Cancer, April 2012
|
| DOI | 10.1186/1471-2407-12-144 |
| Pubmed ID | |
| Authors |
Carl Christoph Schimanski, Markus Möhler, Michael Schön, Eric van Cutsem, Richard Greil, Wolf Otto Bechstein, Susanna Hegewisch-Becker, Götz von Wichert, Matthias Vöhringer, Michael Heike, Volker Heinemann, Marc Peeters, Stephan Kanzler, Stefan Kasper, Friedrich Overkamp, Jan Schröder, Daniel Seehofer, Frank Kullmann, Bernhard Linz, Irene Schmidtmann, Victoria Smith-Machnow, Ines Gockel, Hauke Lang, Peter R Galle |
| Abstract |
15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC. |
Mendeley readers
The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 86 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 19% |
| Student > Master | 9 | 10% |
| Other | 7 | 8% |
| Student > Bachelor | 7 | 8% |
| Student > Doctoral Student | 5 | 6% |
| Other | 19 | 22% |
| Unknown | 23 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 37% |
| Nursing and Health Professions | 7 | 8% |
| Agricultural and Biological Sciences | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Chemistry | 4 | 5% |
| Other | 10 | 12% |
| Unknown | 24 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2015.
All research outputs
#853,750
of 22,664,267 outputs
Outputs from BMC Cancer
#107
of 8,242 outputs
Outputs of similar age
#4,499
of 161,627 outputs
Outputs of similar age from BMC Cancer
#1
of 60 outputs
Altmetric has tracked 22,664,267 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,242 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 161,627 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.